Table 1

Clinical, hematological, and biochemical characteristics of nondiabetic control subjects and pretreatment and posttreatment data for subjects with type 2 diabetes

ParametersNondiabetic subjectsDiabetic subjects pretreatmentDiabetic subjects posttreatmentP
Age (years)50.4 ± 3.851.0 ± 3.151.0 ± 3.1NS
BMI (kg/m2)28.0 ± 0.930.4 ± 0.730.0 ± 0.9NS
Hemoglobin (g/l)14.2 ± 1.813.7 ± 1.413.7 ± 1.2NS
Fasting plasma glucose (mmol/l)5.0 ± 0.110.7 ± 0.5*10.6 ± 0.4<0.001*
A1C (%)5.5 ± 0.19.1 ± 0.2*9.0 ± 0.2<0.001*
Blood urea nitrogen (mmol/l)5.3 ± 0.35.4 ± 0.65.4 ± 0.4NS
Creatinine (μmol/l)88.4 ± 3.479.6 ± 4.279.6 ± 3.8NS
Alanine aminotransferase (U/l)20.4 ± 1.223.8 ± 5.024.4 ± 4.4NS
Aspartate aminotransferase (U/l)17.6 ± 1.418.2 ± 2.417.9 ± 2.6NS
Glutamate (mmol/l)530.1 ± 88.3451.5 ± 120.7482.4 ± 98.2NS
Cysteine (μmol/l)25.2 ± 1.517.8 ± 1.5*25.5 ± 1.9<0.01*
<0.05
Glycine (μmol/l)514.7 ± 33.1403.2 ± 18.2*521.6 ± 19.4<0.01*
<0.01
DROMs (UCarr)286 ± 10403 ± 11*359 ± 10<0.001*
<0.05
<0.01
Lipid peroxide (μmol/l)2.6 ± 0.410.8 ± 1.2*6.2 ± 0.9<0.001*
<0.01
<0.05
  • *Nondiabetic control subjects versus diabetic subjects: pre-treatment.

  • †Diabetic subjects: pretreatment versus posttreatment.

  • ‡Diabetic subjects: posttreatment versus nondiabtic control subjects.